Conference Coverage

ASCO 2018: Dr. Walter M. Stadler gives his top picks in prostate cancer research

Publish date: May 29, 2018

 


• 5007, KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

• 5020, Microsatellite instability in prostate cancer and response to immune checkpoint blockade.

• 5012, Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.

• 5022, Radium-223 retreatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.

Pages

Recommended Reading

New regimen looks good in stage IV favorable histology Wilms
MDedge Hematology and Oncology
Company discontinues phase 3 ADAPT for mRCC
MDedge Hematology and Oncology
World Trade Center responders face greater cancer burden, including greater risk of multiple myeloma
MDedge Hematology and Oncology
Rare paraneoplastic dermatomyositis secondary to high-grade bladder cancer
MDedge Hematology and Oncology
Immediate postresection gemcitabine tops saline in low-grade non–muscle-invasive bladder cancer
MDedge Hematology and Oncology
Female cancer researchers receive less funding than male counterparts
MDedge Hematology and Oncology
Is cancer immunotherapy more effective in men than women?
MDedge Hematology and Oncology
Automated bone scan index predicts survival in metastatic castration-resistant prostate cancer patients
MDedge Hematology and Oncology
IMDC model mirrors mRCC clinical outcomes
MDedge Hematology and Oncology
CBT-I bests acupuncture for treating insomnia among cancer survivors
MDedge Hematology and Oncology